A Long-Term Open-Label Extension Study for Subjects Completing a Phase 3 Efficacy and Safety Study of Lesinurad Monotherapy in Subjects With Gout
Phase of Trial: Phase III
Latest Information Update: 23 Sep 2017
At a glance
- Drugs Lesinurad (Primary)
- Indications Gout
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ardea Biosciences
- 23 Sep 2017 Results related to this study and it's parent/core study (refer CTP: 212123) were published in the Rheumatology
- 06 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 May 2014 Planned End Date changed from 1 Jan 2016 to 1 Aug 2014 as reported by ClinicalTrials.gov.